Dr. Klein graduated from Hamilton, having specialized in neuroscience. He then became a technician for Martin Bähler in Paul Greengard’s laboratory at Rockefeller University in New York, before studying pharmacology at the University of Colorado Health Sciences Center in Denver. After a summer fellowship at a pharmaceutical company in Japan, post-doctoral studies in pharmacology commenced at the University of Florida. His current line of research began there, using gene transfer to the brain to improve the state of affairs for neurodegenerative diseases. Since 2002, the research has progressed in the Department of Pharmacology at the LSU Health Sciences Center in Shreveport, LA, with promotion from Assistant to Associate Professor in 2008. Researchinterests strive to improve the mimicry of animal models to neurodegenerative diseases. While viral vector gene transfer is a central method, the development of a small molecule drug is utmost important to improve therapy, which would also add significance to the models themselves. Dr. Klein was involved in early successes achieving long-term gene transfer to the brain with adeno-associated virus and green fluorescent protein, functional neurotrophic factor gene delivery, and models for  neurodegenenerative diseases relevant to alpha-synuclein, tau, and TDP-43. He has had the opportunity to interact with excellent coauthors, described in about 50 publications. The research was supported by the NIH, The Society for Progressive Supranuclear Palsy, and others.